Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Sim

Pain Medicine Fair Lawn, NJ Medical Doctor

NPI 1912295122 CMS profile 1384257

2-22 Banta Pl, Fair Lawn, NJ 07410

Open in the dashboard

General payments

$5,107

142 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Sim of Fair Lawn, NJ is reported in the CMS Open Payments database as having received $5,107 across 142 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $538 6
2024 General $313 6
2023 General $741 9
2022 General $948 27
2021 General $735 18
2020 General $292 15
2019 General $1,541 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Sim
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Andrew Sim were reported at $538. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Andrew Sim Pain Medicine median Middle half National median
2019 $1,541 $498 $126–$1,682 $163
2020 $292 $284 $80–$910 $114
2021 $735 $399 $112–$1,219 $132
2022 $948 $455 $137–$1,484 $149
2023 $741 $484 $128–$1,495 $160
2024 $313 $498 $131–$1,540 $164
2025 $538 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $1,474 22 payments
  2. Boston Scientific Corporation $914 26 payments
  3. Abbott Laboratories $767 33 payments
  4. Medtronic, Inc. $374 7 payments
  5. Stryker Corporation $334 2 payments
  6. Nalu Medical, Inc. $252 6 payments
  7. BIOTRONIK NRO, Inc. $205 2 payments
  8. Djo, LLC $134 2 payments
  9. Scilex Pharmaceuticals Inc. $82 6 payments
  10. Pfizer Inc. $80 6 payments
  11. Other $493 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,086 141 payments
  2. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. Senza Spinal Cord Stimulation System $572 10 payments
  2. Omnia $534 8 payments
  3. Proclaim Family of SCS IPGs $447 19 payments
  4. Senza $368 4 payments
  5. AVS ANCHOR-L $334 2 payments
  6. SPECTRA WAVEWRITER $311 11 payments
  7. Varithena Administration Pack $262 3 payments
  8. Nalu Neurostimulation System $252 6 payments
  9. INTELLIS ADAPTIVESTIM $248 5 payments
  10. PROCLAIM $189 5 payments
  11. Other $1,756 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

337

Median for Pain Management: 951

Drug cost

$3,442

Median for Pain Management: $26,034

Branded share of claims

15.7%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 43 $904
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 53 $790
Celecoxib Generic 14 $433
Nabumetone Generic 34 $314
Meloxicam Generic 76 $228
Tizanidine Hcl Generic 21 $195
Pregabalin Generic 21 $191
Oxycodone Hcl Generic 13 $160
Cyclobenzaprine Hcl Generic 21 $88
Tramadol Hcl Generic 29 $84

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$304,319

Of which drugs: $3,136

Medicare patients

266

Average age 72

Services billed

2,356

158 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 32%
Ischemic heart disease 29%
Depression 25%
Osteoporosis 21%
Cancer 20%
Chronic kidney disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 54 294 $228

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record